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Intraoperative reductions in serum fentanyl levels in dogs with induced moderate 
hypothermia and transdermal fentanyl patches (TDF) in place has been documented.  The 
impact of such reductions has not been evaluated nor has the anesthetic sparing effect of the 
TDF.  Reductions in serum levels may be the result of either a decreased uptake of fentanyl 
from the dermal depot, or a biophase shift.  The objective of this investigation was to 
determine whether the minimum alveolar concentration (MAC) of isoflurane was altered in 
the presence of TDF in normothermic and hypothermic dogs. 
Six mature, healthy, mixed breed dogs were anesthetized on four separate occasions, 
and received each of the 4 following treatments in random order: 1. Sham patch-
normothermia (C-NORM), 2. Sham patch-hypothermia (C-HYPO), 3. Fentanyl patch-
normothermia (F-NORM), 4. Fentanyl hypothermia (F-HYPO).  The appropriate patch was 
applied twenty four hours prior to induction of anesthesia.  Anesthesia was induced with 
isoflurane in oxygen; the dogs were intubated and mechanical ventilation was initiated. 
Target temperatures (34.5ºC- HYPO, or within 1ºC of baseline- NORM) were held constant 
for one hour prior to beginning the MAC determinations.  Supramaximal stimulation was 
produced by an electrical stimulator which delivered a current to needle electrodes in the 
buccal mucosa of the lower jaw of the dog.  The MAC (± SD) for C-NORM, C-HYPO, F-
NORM and F-HYPO was 1.2 ± 0.17, 0.855 ± 0.183, 0.763 ± 0.097, and 0.830 ± 0.172 
respectively.  MAC for C-NORM was significantly higher than the other groups.  There was 
no significant difference between C-HYPO, F-NORM, and F-HYPO.   
Transdermal fentanyl reduces the isoflurane requirement in normothermic dogs.  The 





















































1.1 Use of Fentanyl in Animals  
Most animals requiring general anesthesia are subjected to a surgical or medical 
procedure.  Many of these procedures are associated with tissue trauma that leads to the 
experience of pain.  In these instances, administration of analgesic drugs, such as opioids, as 
part of a multi-modal approach to pain management is often warranted.  Fentanyl is a mu 
(OP3) opioid agonist, available in injectable, transmucosal, and transdermal preparations that 
is frequently used for the control of pain in animals and people.  Transdermal fentanyl (TDF) 
has been used in pain management protocols in people, dogs, cats, horses, rabbits, sheep, 
goats and pigs (Broome et al. 1995; Kyles et al. 1998; Glerum et al. 2001; Matthews et al. 
1997; Foley et al. 2001; Dowd et al. 1997; Carroll et al.1999; and Harvey-Clark et al. 2000).   
1.2 Use of Fentanyl in People 
Transdermal administration of fentanyl is contraindicated in people for management 
of acute or post-operative pain because of the potential for profound respiratory depression 
(Grond et al. 2000).  In addition, the non-titratable nature of transdermal drug delivery 
systems may make them unsuitable for the delivery of immediate post operative analgesia.  
Instead, postoperative analgesic needs are often managed using a patient controlled 
administration device while the TDF delivery system is used primarily for the management 
of chronic pain in people with cancer.   
The use of a patient controlled system is not feasible in animals, therefore other types 
of delivery system must be considered.  Transdermal delivery systems for fentanyl provide a 
convenient form of dosing a mu opioid agent. Such a system provides longer term pain 
management of up to 72 hours for animals in the 24-36 hours following surgery compared 
with bolus injections or oral medications; the need for additional equipment or invasive 
catheters is also negated. 
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1.3 Respiratory Depression in Dogs 
Respiratory depression via direct depression of the brain stem respiratory centers is 
associated with the administration of mu opioid agonists in people.  Hypoventilation after 
surgery is not observed in dogs that have received high doses (average dose of 4.8µg/kg/hr) 
of fentanyl transdermally beginning 24 hours prior to surgery and continued for 48 hours 
following surgery (Welch et al, 2002).  The lack of associated respiratory depression in dogs 
may make TDF a suitable choice for analgesia during surgery and for the first 48 hours 
following surgery. 
1.4 Post-operative Analgesia 
 Transdermal fentanyl is used frequently for pain management in the 48 hours 
following surgery.  Transdermal fentanyl provides equal or better analgesia than epidural 
morphine in dogs undergoing orthopedic surgery (Robinson et al. 1999).  Cats undergoing 
onychectomy demonstrate better recovery scores (e.g. less vocalizing), lower levels of 
sedation, and lower pain scores after receiving fentanyl transdermally compared to cats 
receiving butorphanol intravenously (Franks et al. 2000).  The transdermal system offers 
ease of administration, decreased frequency of dosing, no need for venous access or frequent 
intramuscular injections, and also the ability to provide analgesia to animals on an outpatient 
basis. 
1.5 Inhalant Anesthetic Reductions 
The TDF patch is often applied 24 hours before surgery.  This allows time 
(approximately 24 hours) for the drug to reach serum concentrations that provide analgesia, 
prior to the surgical trauma, although variations occur between species and individual 
animals.  In addition, the presence of a mu opioid agonist during surgery should reduce the 
inhalant anesthetic requirements (Steffey et al. 1994).  This reduction in inhalant 
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concentration may be associated with significant reductions in the negative cardiovascular 
effects of the inhalant (Muir et al. 2003). 
  In normothermic cats receiving fentanyl transdermally, the requirement for 
isoflurane is significantly reduced (Yackey et al, 2004).  Interestingly, cats anesthetized with 
isoflurane in the presence of moderate hypothermia show significant reductions in serum 
fentanyl levels during the anesthesia period(Pettifer and Hosgood, 2003).  Dogs with 
moderate hypothermia also show significant reductions in serum fentanyl concentrations 
during anesthesia (Pettifer and Hosgood, 2004).  The effect of these reductions in serum 
fentanyl concentrations on inhaled anesthetic requirements in dogs and cats with moderate 
hypothermia during anesthesia is not known.   
 Reductions in serum fentanyl concentrations during anesthesia associated with 
hypothermia may be the result of decreased uptake of fentanyl from the dermal depots.   
Changes in peripheral perfusion could alter the uptake of fentanyl and result in decreased 
effectiveness of a TDF patch during the anesthesia period.   In contrast, volatile anesthetics 
also play a role in alterations in peripheral circulation which vary with the individual 
inhalants.  Isoflurane administration causes mild peripheral vasodilation which could 
increase the uptake of fentanyl administered via the transdermal route.   
 The decrease in serum fentanyl concentrations in hypothermic dogs may not be due 
to a decrease in uptake at all.  It is possible that the decreased serum fentanyl concentration 
was a result of the fentanyl moving from the serum to the site of action (or biophase) in the 
interstitial fluid.  If this occurred, an increase in pharmacologic effect manifested by lower 
inhalant concentrations despite the reduced serum fentanyl concentrations might be 
expected. 
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 This investigation is an assessment of the impact of the transdermal administration of 






























2.1 Pain (nociception)  
Pain or nociception has been defined by the International Association for the Study 
of Pain as “an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage” (Merskey, 1979).   
The experience of pain may be exhibited in various ways and involves complex and 
dynamic biological sequences which change with the type and duration of associated 
stimulation.  Pain has been classified in a number of ways that describe the sensation but 
imprecisely document pain.  Somatic pain describes that which is well localized, sharp and 
definite, often constant and occurring at the site of the stimulus.  In contrast, visceral pain 
may be poorly localized, vague or dull, and periodic in nature.  Inflammatory pain describes 
pain associated with the release of inflammatory mediators in response injury.  Physiologic 
pain serves as a protective mechanism to prevent the body from potential injury.  Pathologic 
pain describes pain in an area of sensory loss, or in the absence of ongoing tissue damage in 
conjunction with allodynia (the experience of pain associated with non painful stimuli) and 
hyperalgesia (an increased response to stimulus).  Pain may also be described as fast pain or 
slow pain depending on the nerve fibers involved in transmitting the signals to the central 
nervous system. 
Fast pain is the result of stimulation of small, myelinated A-delta nerve fibers with a 
conduction velocity of 6 - 30 m/s.  Stimulation of fast pain fibers is associated with 
mechanical (mechanosensitive) and/or thermal (mechanothermal) stimuli such as a pin prick 
or a surgical incision. 
Slow pain is associated with stimulation of unmyelinated type C nerve fibers with a 
conduction velocity of 0.5 – 2 m/s.  Stimulation of slow pain fibers is associated with 
mechanical, thermal or chemical (polymodal) stimulation and causes throbbing or aching 
types of pain.   
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Chemicals capable of activating nociceptors include bradykinin, serotonin, histamine, 
acetylcholine, and potassium ions.  Substance P (an 11-amino acid peptide) does not directly 
excite nociceptors, but when released from nerve endings it results in vasodilation and an 
increase in vascular permeability (Dahl and Kehlet, 1991).  Prostaglandins are also involved 
indirectly in that they sensitize nociceptors but are unable to excite them directly. 
2.2 Physiolgical Processes Involved in Nociceptive Pathways 
 
The four major physiologic processes involved in the nociceptive pathway are: 
1. Transduction of the noxious stimuli into electrical activity at the sensory nerve 
endings. 
2. Transmission of the impulses throughout the sensory nervous system. 
3. Endogenous modulation or modification of nociceptive transmission.  
4. Perception of pain. 
2.2.1 Transduction 
Nociceptive receptors must be present in order to detect stimuli to initiate the pain 
pathway.  Nociceptors (peripheral receptors) are naked afferent nerve endings of myelinated 
A-Delta or unmyelinated C fibers that encode occurrence, intensity, duration, and location of 
noxious stimuli.  The stimuli can be mechanical, thermal, or chemical in nature.  The type of 
pain perceived will depend in part on the nerve fibers involved in the conduction of the 
impulse.  Four classes of nociceptors have been identified: mechanical, thermal, polymodal, 
and silent.
Nociceptive neurons that are activated by noxious stimuli change or transduce these 
stimuli into electrical signals and generate action potentials in afferent A-delta and C nerve 
fibers.  Transduction is mediated by membrane bound receptors that are activated according 
to the type of stimulation.  Noxious mechanical stimuli are mediated by acid sensing ion 
channels (ASIC) (Page et al. 2004) thermal stimuli by vanilloid receptor-1 (VR1) (Nagy et 
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al. 2004), and chemical stimuli by purinergic receptor subtype-3 (P2X3) (Wu et al. 2004).  
Sensory impulse generation begins when a stimulus causes an increase in the permeability of 
the membrane of sensory endings to various ions.  Ions flow through channels following 
their electrical and concentration gradients producing partial depolarization of sensory 
endings (generator potential).  In addition to the slow generator depolarization, there is a 
triggering of more sensitive sodium channels which augments depolarization and is often 
referred to as a spike or nerve impulse.   
2.2.2 Transmission 
Electrical impulses that are generated from the transduction of the input to the 
nociceptors are transmitted to the spinal cord by A-Delta or C fibers which have cell bodies 
located in the dorsal root ganglia.  Neurons in nociceptive pathways synapse with local 
interneurons or projection neurons in the dorsal horn of the spinal cord.  In the dorsal horn of 
the spinal cord, the release of excitatory neurotransmitters such as glutamate, neurokinins 
(substance P), tachykinins, and calcitonin gene-related peptide, are required for further 
transmission of pain to higher centers in the thalamus, brainstem, and cerebral cortex via 
multiple spinal cord pathways (Hudspith, 1997; Yaksh and Hammond, 1982).   
The spinal cord pathways are divided into two groups based on location.  The lateral 
group includes the neospinothalamic tract, the spinocervical tract, and the dorsal column-
postsynaptic tract.  The medial group includes the paleospinothalamic tract, the 
spinoreticular tract, the spinomesencephalic tract, and the propriospinal tract.  There are 
major interspecies differences in these systems, for example the spinocervical tract is well 
developed in cats but not in primates (Dennis and Melzack, 1977). 
2.2.3 Endogenous Modulation of Nociceptive Transmission 
Transmission of impulses is modulated by the activation of descending inhibitory 
pathways that extend between the brain and spinal cord.  A descending pathway has four 
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components; A. Cortical and diencephalic, B. Mesencephalic periaqueductal gray matter and 
periventricular gray matter, C. Rostroventral medulla and pons of midbrain, and D. 
Medullary and spinal cord dorsal horn (Cousins and Mather,1984). 
2.2.3.1. Cortical and Diencephalic 
Structures such as the spinal cord which project fibers to the brain also receive 
descending fibers from the cortex.  This cortical input influences cephalad transmission at 
the level of the thalamus, reticular formation, trigeminal system, and spinal cord.  These 
structures in turn influence cephalad transmission of impulses to lower synapses including 
reticulospinal and rubrospinal which project to several laminae of the spinal cord (Cousins 
and Mather, 1984). 
2.2.3.2. Mesencephalic Periaqueductal Grey Matter (PAG) and Periventricular Gray 
Matter (PVG) 
  
The mesencephalic PAG and PVG are substantial contributors to the endogenous 
analgesic system (Carsten et al. 1979). Antinociceptive effects are thought to be mediated 
largely by endogenous opioid activation of the PAG outflow, probably operating through a 
gama-aminobutyric acid (GABA) containing interneuron.  In addition the PAG has direct 
descending projections to the dorsal horn and ascending projections to the intralaminar 
nuclei of the thalamus (Lamont et al. 2000). 
2.2.3.3. Rostroventral Medulla and Pons of the Midbrain 
A large population of brain stem cells in the ventral rostral medulla and caudal pons 
project to the dorsal horn.  These cells are concentrated in the nucleus raphe magnus, and the 
nucleus reticularis magnocellularis.  These nuclei receive input from the PAG, send fibers to 
the spinal cord, and produce antinociception (inhibition of the perception and/or transmission 
of pain) when stimulated (Coggeshall et al. 1981; Willis, 1985; Yaksh and Hammond, 1982; 
Mantyh, 1983). 
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2.2.3.4.  Medullary and Spinal Cord Dorsal Horn 
Communication between dorsal horn neurons is complex.  The role of the dorsal horn 
in antinociception was first acknowledged by Melzack and Wall.  They proposed a theory 
now widely recognized as the gate control theory (Melzack and Wall, 1965).  They theorized 
the activity of large afferent fibers can cause the inhibition of smaller fibers which are 
generating the nociceptive impulses, for example, the application of an irritating ointment or 
poultice to produce pain relief.  The mechanism by which this process occurs involves 
inhibitory and excitatory neurotransmitters working in concert. 
Each neuron may be influenced by many neurotransmitters which have different 
actions in a given region.  Multiple neurotransmitters may exist within separate intra-
neuronal vesicles in a single neuron. Both excitatory and inhibitory neurotransmitters are 
produced, stored, and released in terminals of afferent nerve fibers and dorsal horn neurons.  
These neurotransmitters are involved in the transmission of nociceptive signals between 
neurons.   
Glutamate and aspartate are the major excitatory neurotransmitters in the central 
nervous system (CNS).  Other important excitatory neurotransmitters include substance P, 
neurotensin, vasoactive intestinal peptide, and cholecystokinin (Lamont et al., 2000).    
GABA is the major inhibitory neurotransmitter in the CNS, being present in many 
areas including the cerebral cortex and spinal cord.  Glycine is the principal inhibitory 
neurotransmitter in the spinal cord.  Serotonin, norepinephrine, and the endogenous opioid 
peptides (enkephalins, endorphins, and dynorphins) have been identified in dorsal horn 
neurons and produce inhibitory effects on nociceptive transmission (Cousins and Mather, 
1984).   
Excitatory neurotransmitters are released in response to activation of the nociceptive 
pathway by a noxious stimulus.  The endogenous opioid system may respond in conjunction 
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with other inhibitory neurotransmitters to modulate and decrease the effects of the excitatory 
neurotransmitters.   
2.2.4 Perception  
Pain is perceived following the successful transduction, transmission, modulation, 
and processing of nociceptive input at the cerebral level.  Pain is a conscious, subjective and 
emotional experience.  Perception of pain in people is influenced by environmental, 
educational, social, cultural, and individual factors.  Determination of an animal’s perception 
of pain remains one of the greatest challenges for the veterinarian.  Many species may mask 
pain as a survival mechanism, or behavior associated with the perception of pain may go 
unnoticed by an observer.  Unlike people, animals cannot verbally quantify the pain they 
perceive.  Veterinarians must rely on physical signals from the animals in their determination 
of whether the animal is painful. 
2.3 Peripheral Sensitization 
 Peripheral sensitization is an increase in sensitivity of A-delta, A-beta and C fibers 
which enables low intensity stimuli to cause pain.  The sensitization occurs as a direct 
response to the release of inflammatory mediators including bradykinin, serotonin, 
histamine, potassium ions, and hydrogen ions following tissue trauma and inflammation 
(Rang et al. 1991).  Damage to cells also results in activation of the arachidonic acid 
pathway and production of prostaglandins and leukotrienes.  A combination of the 
inflammatory mediators and arachidonic acid metabolites act synergistically to convert the 
high threshold nociceptors to low threshold nociceptors so that the application of low 
intensity stimuli will now result in receptor activation (Houghton et al. 1997).  The perceived 




2.4 Central Sensitization 
Central sensitization refers to the alteration of responses in dorsal horn neurons 
associated with sustained afferent impulse activity from the summation of action potentials 
that occurs due to slow synaptic potentials (lasting up to 20 seconds) of A-Delta and C 
fibers.  A progressive, long lasting depolarization in the dorsal horn neurons develops.  Just a 
few seconds of C fiber input can generate several minutes of postsynaptic depolarization.    
This process is often termed “wind-up” and is mediated by both N-methyl-D-aspartate 
(NMDA) receptors that bind glutamate and tachykinin receptors that bind substance P and 
neurokinin A (Thompson et al. 1990; Woolf and Wall, 1986).   Wind-up results in an increase 
in the second messenger protein kinase (as a result of G protein receptor activation) which 
provides positive feedback to the NMDA receptors, thereby increasing their efficacy (Woolf 
and Chong, 1993).  The outcome of central sensitization is hypersensitivity to noxious 
stimuli and allodynia.   
2.5 Hyperalgesia 
 
 Pathologic pain from tissue trauma causes an increase in sensitivity in areas not 
adjacent to the nociceptive stimulus or tissue injury.  This area of heightened sensitivity is 
referred to as the zone of secondary hyperalgesia.  Secondary hyperalgesia develops with the 
recruitment of A-beta fibers that are normally associated with specialized, low threshold 
peripheral mechanoreception.  These fibers generate innocuous sensations; but once central 
sensitization occurs they contribute to nociception. The metabolites of arachidonic acid and 
bradykinin also play a role in sensitization (Dahl and Kehlet, 1991).   Inhibition of peripheral 
and central sensitization processes is achieved by preemptive analgesia; the initiation of 





2.6 Multimodal Approach to Analgesia 
 
Multimodal analgesia refers to the clinical practice of combining drugs and routes of 
administration with other techniques (such as acupuncture) to achieve additive or synergistic 
effects.  For example, pain associated with intervertebral disk disease or invasive soft tissue 
neoplasias are likely to have both inflammatory and neuropathic components.  Effective pain 
management targets transduction, transmission, perception, and modulation pathways.  The 
major drug categories used in multimodal analgesia include local anesthetics, non steroidal 
anti-inflammatory drugs, alpha2-adrenergic agonists, NMDA antagonists, and opioids.  
These drugs can be administered in a variety of ways, for example intravenously via a 
constant rate infusion (NMDA antagonism with Ketamine), or transdermally (fentanyl). 
2.6.1 Local Anesthetics   
Local anesthetics administered topically, intra-dermally, peri-neurally, intrathecally 
and epidurally act by blocking sodium channels and preventing impulse transmission, they 
also inhibit modulatory nociceptive processing when administered epidurally or intrathecally 
(Butterworth and Strichartz, 1990, Brown et al. 1990, and Feldman and Covina, 1988).  
Local anesthetics are applied directly at the target site and absorption into the systemic 
circulation is not required for analgesia.  These drugs inhibit nociception by blocking the 
transduction of impulses.  Epidural or subarachnoid administration can also inhibit 
transmission via peripheral nerves or plexuses.  Local anesthetic solutions introduced via 
these routes act on superficial layers of the spinal cord, but the principal site of action is at 
the preganglionic fibers as they exit the spinal cord.   
2.6.2 Non Steroidal Anti-inflammatory Drugs (NSAIDs)   
The arachadonic acid pathway involves the production of mediators involved in 
inflammation such as prostaglandins. Enzymes involved in the pathway include 
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cyclooxygenase (COX) (which include two isoforms, COX 1 and COX 2) and lipoxygenase 
(LOX).  
NSAIDs inhibit cyclooxygenase and lipoxygenase activity and thus prevent synthesis 











Figure 1.  The Arachidonic acid cascade.  HPETE = hydroperoxyeicosatetaenoic 
acid; HETE = hydroxyeicosatetraenoic acid; PGG = prostaglandin G; large arrow indicates 
inhibition of enzymes by NSAID. 
 
The decreased production of these alogenic substances i.e. prostaglandins, will 
obtund transduction.  The mechanism of inhibition of cyclooxygenase varies among 
NSAIDs.  Inhibition of prostaglandin synthesis decreases the inflammatory response to 
surgical trauma. 
Preoperative administration can decrease postoperative pain and requirements for 
opioids (Souter et al., 1994) but it is important to note that renal blood flow depends on 
prostaglandins for release of renin (especially if blood volume is reduced) and 
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recommendations have been made to withhold NSAIDs prior to surgery because of the risk 
of renal impairment (Clive and Stoff, 1984). 
Adverse reactions to NSAIDs are common including gastrointestinal effects such as 
erosions, renal effects such as tubular necrosis, coagulation effects as a result of alterations 
in platelet aggregation, and interactions with other drugs.     
2.6.3 Alpha2-adrenergic Agonists   
Alpha2-adrenergic agonists bind to 3 receptor types referred to as α2a, α2b, and α2c 
(Bylund et al. 1994).  These receptors are distributed throughout the body, including the 
dorsal horn of the spinal cord (site responsible for analgesic actions) and the locus coeruleus 
of the brain stem (site responsible for sedative effects) (Correa-Sales et al. 1992).  The α2a 
receptors mediate sedation, hypnosis, analgesia and sympatholysis (Lakhlani et al. 1997   
Alpha2-adrenegic agonists modulate the release of substance P and other neurotransmitters 
involved in nociception possibly via interactions with other receptors such as opioid and 
cholinergic.  The positive impact on modulation of nociceptive transmission using this class 
of drugs is beneficial in multimodal pain management.   
2.6.4 N-methyl-D-aspartate Antagonists   
Ketamine (a phencyclidine derivative) is a non competitive antagonist of the NMDA 
glutamate receptor (Lodge and Anis, 1982).  Ketamine also interacts with the phencyclidine 
binding receptor which causes inhibition of activity at the NMDA receptor. The action of 
ketamine at receptor sites in the dorsal horn prevents central sensitization (Stubhaug et al 
1997).  Administration can be intramuscularly, intravenously, (bolus or continuous rate 
infusion), epidurally, or topically (Kronenburg, 2002).   
2.6.5 Opioids   
Opioid descibes all exogenous substances that bind to opioid receptors and produce 
an agonistic (morphine-like) effect.  Opioids may be naturally occurring (morphine), 
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synthetic (methadone) or semi-synthetic (fentanyl).  Opioids are characterized based on 
specific receptor activity as agonists e.g. fentanyl, or agonist/antagonists e.g. butorphanol.  
Morphine is the prototype opioid and offers comparisons to other opioids.  
2.7 Opioid Receptors 
2.7.1 Classification and Distribution of Opioid Receptors 
Opioid receptors are classified as mu, delta and kappa receptors (Atcheson and 
Lambert, 1994).  The original classification established in the 1970’s was based on the 
response patterns in the chronic spinal dog model to three different opioid compounds 
(Martin et al. 1976).  The receptors were named after the drugs used in this original study: 
mu (morphine), kappa (ketacyclazocine), and sigma (SKF 10,047).  Subsequently, it has 
been determined that the sigma receptor is not an opioid receptor but rather a high affinity 
binding site for phencyclidine and similar compounds (Pleuvry, 1991).  In 1977, a binding 
site in the mouse vas deferens that had a high affinity for enkephalins was identified and 
named delta receptor (Takemori et al. 1986).  Epsilon receptors were also identified in the rat 
vas deferens but are no longer considered opioid receptors.  Attempts to detect epsilon 
opioid receptors in tissue other than the rat vas deferens have been unsuccessful (Contet et 
al. 2004).   More recent advances in molecular cloning have led to the renaming of these 
receptors as OP1 (delta), OP2 (kappa), OP3 (mu), and ORL1 (opioid like receptor 1), (Singh 
et al. 1997).  The ligand for ORL1 is orphanin FQ/nociceptin (Meunier, 1997).  Early work 
suggests that this receptor is widespread but the exact nature of its functions remain 
controversial at this time (Kieffer, 1995).  An interplay with the endogenous opioid system 
has been suggested (Grisel and Mogil, 2000; Reinscheid et al., 2000).  The endogenous 
opioid system is activated by three endogenous peptide opioid receptor ligands referred to as 
enkephalins, endorphins, and dynorphins (Atcheson and Lambert, 1994).   
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Two subpopulations of mu receptors are responsible for either analgesia (mu1) or side 
effects such as hypoventilation, bradycardia, and physical dependence (mu2).  Endorphins 
act on the mu1 receptors.  Kappa agonists, such as dynorporhin, produce less respiratory 
depression, but high intensity painful stimuli may be resistant to the effects of these 
substances.  Some opioid agonist-antagonists such as butorphanol act mainly on these kappa 
receptors.  Delta receptors respond to enkephalins and may be more important in spinal 
analgesia. They may modulate the activity of mu receptors.    
Until the late 1980’s opioids were believed to act predominantly centrally but it has 
become clear that opioid receptors are also present in the peripheral nervous system (Stein, 
1995).   
2.7.2 Cellular Mechanisms 
Opioid receptors are a subset of G protein-coupled receptors that include muscarinic 
receptors and somatostatin receptors.  Amino acid sequences in opioid receptors demonstrate 
considerable homology with somatostatin receptors but not with other receptors in this 
group.  Opioids have direct (presynaptic) and indirect (post synaptic) effects (Yaksh, 1997; 
Trafton et al., 2000).  Opioid receptor activated G protein effector systems have short term 
effectors such as potassium and calcium ion channels which result in rapid but short lasting 
effects and long term effector systems involving second messengers such as cyclic adenosine 
monophosphate (cAMP) responsible for more slowly occurring but longer lasting effects.  
Changes in cAMP are able to modulate the release of other important neurotransmitters such 
as substance P (Stein 1995).  All opioid receptors prevent the opening of voltage dependent 
calcium channels, decreasing neurotransmitter mobilization and release.   




2.8 Fentanyl  
Fentanyl is a pure mu receptor agonist considered to be 75 to 125 times more potent than 
morphine.  Fentanyl (N-Phenyl-N-(1-2-phenylethyl-4-piperidyl) propanimide) is a synthetic 
phenylpiperidine derivative structurally related to meperidine.  The empirical formula for 
fentanyl is C22H 28N2O (figure 2). 
  
N-CH2CH2CH2CH2CON
Figure 2.  The chemical structure of fentanyl  
2.8.1 Routes of Administration 
Fentanyl is normally administered via intravenous injection, as a bolus or as a 
continuous rate infusion.  Transmucosal delivery is possible and is especially useful for 
relieving preoperative anxiety and facilitating a smooth anesthetic induction in children 
(Zeltzer et al., 1989).  Transmucosal fentanyl is administered in the mouth via a attached to a 
handle (Feld et al., 1989; Macaluso et al., 1996; Stanley et al., 1989).  Administration of 
transdermal fentanyl via a patch adhered to the skin is used in people and various species.   
2.8.2 Pharmacokinetics  
 Fentanyl is highly lipid soluble with a rapid onset of action following intravenous 
administration.  Lipid solubility facilitates the passage of the drug across the blood brain 
barrier.  The short duration of action of fentanyl reflects the rapid redistribution of fentanyl 
to inactive sites such as muscle and fat, with an associated decrease in plasma concentrations 
(Hug and Murphy, 1981).  Seventy five percent of the initial intravenous dose of fentanyl 
undergoes first pass pulmonary uptake (Roerig et al. 1987).  The lungs act as a large inactive 
storage site and limit the initial amount of drug that reaches the systemic circulation.  
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Table 1.  Effects of short- and long-term administration of opioids 
 









Nausea and vomiting 





Long-term Tolerance to effects of drug 
Physical dependency 
 
In the presence of continuous delivery of fentanyl there is progressive saturation of inactive 
sites resulting in protracted clearance and sustained plasma concentrations of the drug.   
 After intravenous administration fentanyl demonstrates an extensive extravascular 
volume of distribution, a medium to high total body clearance, and a low renal clearance.    
There are large variations in reported pharmacokinetics of fentanyl (Grond et al. 2000).  
Such variations are produced by variation in the fentanyl assays used, the pharmacokinetic 
models, and route of administration.   
The presence of fentanyl in the systemic circulation after transdermal application is 
determined not only by skin permeability, but also by local blood flow.  Only extreme 
variations in blood supply influence fentanyl absorption (Grond et al. 2000).   
In dogs and cats there is considerable interspecies variation in both the time to 
achieve steady state concentrations (consistent concentrations over time) and durations of 
action following application of a TDF patch.  In dogs, steady state plasma concentrations are 
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reached after 24 to 36 hours (Egger et al. 1998; Kyles et al. 1996).  In cats steady-state 
plasma concentrations are reached after 2 to 18 hours (Scherk-Nixon, 1996; Lee et al. 2000).  
The time to steady state plasma fentanyl concentrations is influenced by the rate of drug 
release from the patch, absorption of drug across the epidermis and dermis, uptake by 
cutaneous vasculature and patient volume of distribution and clearance.   
Following removal of a transdermal fentanyl patch there is a gradual drop in serum 
fentanyl concentrations due to ongoing absorption from the skin depot.  A gradual decline in 
plasma fentanyl concentration to 50% of previous concentrations after approximately 17 
hours was observed in dogs (Varvel et al. 1989).  Other reports indicate the terminal half life 
of the drug to be 13 to 15 hours (Broome et al. 1995).  Thus beneficial effects of the drug 
may be evident even after removal of the patch, however, there is also potential for adverse 
affects such as respiratory depression.   
Bioavailability of fentanyl during transdermal administration can be calculated by 
dividing the plasma concentration by the amount of drug absorbed from the transdermal 
patch.   Varvel et al. (1989) demonstrated that 92% of the fentanyl dose being administered 
transdermally reaches the systemic circulation as unchanged fentanyl, indicating that 
fentanyl biotransformation during transdermal penetration is negligible (8%).   
Upon removal of a patch, considerable drug still remains unused.  In humans, 
following 72 hours of application, between 28 and 85% of the original fentanyl content still 
remains in patches (Marquardt et al. 1995).  Cases of abuse of fentanyl remaining in TDF 
patches have been documented in the human literature; the potential for abuse is no less real 






Fentanyl is metabolized by N-demethylation in the liver.  The metabolite norfentanyl 
is excreted by the kidneys and can be detected in urine for 72 hours following a single 
intravenous injection.  Compared to morphine, fentanyl has a longer elimination half time 
(i.e. the time taken for serum fentanyl concentrations to decrease to 50% of the peak serum 
concentration) due to the larger volume of distribution of fentanyl (both morphine and 
fentanyl have similar clearance rates).  The larger volume of distribution of fentanyl is 
because it is more lipid soluble and subsequently has a more rapid movement into tissues. 
2.8.4 Pharmacodynamics 
The interaction of a drug with a specific protein molecule (or receptor) in the lipid 
bilayer of cell membranes is one of the most important ways in which a drug exerts 
pharmacologic effects.  Fentanyl interacts primarily with the mu opioid receptor.  Opioid 
receptors are located at pre and post synaptic sites throughout the central nervous system and 
in peripheral tissues.  Intracellular events that follow activation of the mu opioid receptor 
include increased potassium conductance and calcium channel inactivation via G proteins, 
the ensuing hydrolysis of guanine triphosphate (GTP) to guanine diphosphate (GDP) 
releases energy which is then used by the activated G protein to interact with effector 
systems (such as potassium ion channels) resulting in recognizable clinical results such as 
analgesia (Atcheson and Lambert, 1994).  An immediate decrease in neurotransmitter occurs 
mainly as a result of presynaptic inhibition of neurotransmitter release (de Leon-Casasola 
and Lema, 1993), although postsynaptic inhibition can also occur (Atcheson and Lambert, 
1994). 
The concentration of fentanyl required to obtain a certain analgesic effect depends on 
several factors including the intensity of the pain, and receptor regulation. 
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2.8.5 Antagonism  
Very small changes in the structure of an opioid can result in the formation of an 
opioid antagonist (Glass et al. 1994).  The substitution of an alkyl group for a methyl group 
on an agonist is a common change employed to manufacture an opioid antagonist.  
Naloxone, naltrexone, and nalbuphine are pure mu antagonists (i.e. their administration 
results in displacement of the agonist from the receptor).  These drugs have a very high 
affinity for mu opioid receptors.   
Partial antagonism can also be achieved by using an agonist-antagonist drug such as 
butorphanol.  Butorphanol is an agonist at the kappa receptor but antagonist at the mu 
receptor (Vandam, 1980).  Utilization of this type of antagonism may confer some degree of 
analgesia (mediated by the kappa receptor in this example) (Lemke et al. 1996; McCrackin 
and Harvey, 1992; Dyson et al. 1990; Bowdle, 1987).   
2.9 Transdermal Fentanyl 
 
Transdermal fentanyl patches were introduced to the veterinary market in 1991 and 
are marketed under the trade name Duragesic®.  Four doses are available; 25µg/h, 50µg/h, 
75µg/h, and 100µg/h, with corresponding patch sizes of 10, 20, 30, and 40 cm2, respectively.   
Fentanyl is suitable for transdermal administration because of its physiochemical 
properties (such as lipophilicity and molecular weight) and its high analgesic potency 
(requiring only small volumes) (Bailey et al., 2000).  The skin normally acts as a barrier and 
protects the body from injury.  In order for any drug to permeate the intact skin, it must have 
a low molecular weight (≤ 1000g/mol) and high solubility in oil (Grond et al. 2000).  
Fentanyl has a molecular weight of 289g/mol and is highly lipophilic (Grond et al. 2000).  
The skin flux of fentanyl is about 1000 times greater than morphine in human cadaver skin 
(Roy and Flynn, 1989).  
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2.9.1 Components of a Transdermal Fentanyl Patch 
The transdermal delivery system or patch is composed of four functional layers and a 
protective liner.  The first protective layer is removed immediately prior to application of the 
patch.  The next layer is a silicone adhesive layer that contains fentanyl and allows free 
diffusion which delivers an initial bolus upon application.  The third layer is a rate limiting 
ethylene-vinyl acetate copolymer membrane which limits the diffusion of fentanyl from the 
drug reservoir behind the membrane.  The drug reservoir also contains a small amount of 
alcohol (0.1ml per 10cm2) which acts as an absorption enhancer by increasing vasodilation, 
therefore reducing variation in absorption. The fentanyl and alcohol are gelled with 
hydroxyethyl cellulose.  The final outermost layer is a polyester film which prevents escape 




Figure 3.  Transdermal fentanyl patch 
 
2.9.2 Application of a Transdermal Fentanyl Patch 
 Haired areas should be clipped with scissors (not shaved), cleansed and allowed to 
dry prior to application of the patch.  This prevents potential irritation that may be caused by 
clippers, which could increase absorption of the drug (Gilberto et al. 2003).  The patch is 
usually applied to areas on the thorax or dorsum.  Alterations in absorption have been 








dogs).  The application of an adhesive wrap or light bandage may be of benefit to prevent the 
patch from being removed by the animal.  It is not recommended to glue or staple patches in 
place.  Care must also be taken to prevent inadvertent heating of the area in the proximity of 
the patch as absorption could be greatly enhanced resulting in a potential overdose. 
Absorption of transdermal fentanyl may also be altered by variations in blood flow, state of 
hydration, skin and body temperatures (Kyles, 1998; Kyles et al., 1996). 
2.9.3 Plateau Serum Fentanyl Concentrations Following Application 
In people, serum fentanyl concentrations during transdermal administration reach a 
plateau approximately 36 hours after application of the patch (Gourlay et al. 1989), in dogs 
24 hours (Egger et al. 1998; Kyles et al. 1997; Schultheiss et al. 1995; Robinson et al. 1999), 
in horses 4 hours (Matthews et al. 1997), and in cats, from 2 to 18 hours (Franks et al. 2000).  
There is considerable variation in the terminal half life of the drug after removal of the patch.  
It takes up to 17 hours in people for terminal half life to be reached (due to continued 
absorption from a peripheral reservoir believed to be in the stratum corneum) (Varvel et al. 
1989).  Concentrations slowly decrease as fentanyl stored in inactive tissue sites such as fat, 
skeletal muscles and the lungs are depleted (Hug and Murphy, 1981; Roerig et al. 1987).  In 
dogs, a mean of 99 minutes is reported (Kyles et al. 1996).  The longer terminal half life in 
people is the result of saturation of cutaneous fat that continues to release fentanyl after 
removal of the patch. 
2.9.4 Side Effects  
2.9.4.1. Cardiovascular 
Unlike other naturally occurring opioids, fentanyl does not cause release of 
histamine, even at high doses, therefore hypotension as a result of dilation of venous 
capacitance vessels is unlikely to occur (Roscow et al. 1982).  Fentanyl will depress 
baroreceptor reflex control of heart rate more than morphine (Murat et al. 1988).  Subsequent 
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reductions in heart rate may occasionally result in hypotension, especially in neonates 
normotension is primarily heart rate dependant. (Murat et al. 1988). 
2.9.4.2. Respiratory 
People are particularly sensitive to opioid mediated respiratory depression (Becker et 
al. 1976) and transdermal administration of fentanyl in the post-operative period is 
contraindicated.  Significant post-operative hypoventilation is not observed  in dogs despite 
the delivery of relatively high doses of fentanyl from the transdermal system (average 
4.8µg/kg/hr) (Welch et al. 2002).   
2.9.4.3. Non Cardiopulmonary 
Gastrointestinal effects of opioids include spasms of the gastrointestinal smooth 
muscle which decreases peristalsis and enhanced tone of the pyloric sphincter (Allescher et 
al., 1988; Smith et al., 2004; Bayguinov and Sanders, 1993).  Constipation associated with 
decreased peristalsis and prolonged transit time of ingesta is observed in people but not in 
small animals.   
Vomiting is caused by direct stimulation of the chemoreceptor trigger zone in the 
area of the postrema of the medulla, possibly through delta receptors (Watcha and White, 
1992).   
Increases in urine production may be associated with decreases in production of 
antidiuretic hormone and atrial natriuretic peptide (Pesonen et al. 1990).  The incidence of 
urinary retention varies and is likely due to an interaction of the opioid with the opioid 
receptors in the sacral spinal cord (Rawal et al. 1983).  It is more common with neuraxial 
opioids than intravenous or intramuscular.  The interaction inhibits sacral parasympathetic 
nervous system outflow resulting in relaxation of the detrusor muscle and an increase in 
bladder capacity.  With systemic opioid administration urinary urgency is a result of 
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augmentation of the detrusor muscle tone but enhanced sphincter tone making voiding 
difficult. 
2.9.5 Therapeutic Uses in Veterinary Medicine 
Fentanyl is used across species, intravenous low doses (1-2 µg/kg) for analgesia, or 
higher doses (50-150µg/kg) with other agents for anesthesia.   
In dogs undergoing major orthopedic surgery, transdermal fentanyl provided equal or 
greater analgesia than did epidural morphine (Robinson et al. 1999).   In cats undergoing 
onychectomy, transdermal fentanyl allowed cats better recovery scores, lower sedation 
scores, and lower pain scores than did intravenous butorphanol (Franks et al. 2000).  
Recent work by Pettifer et al. in hypothermic and normothermic cats evaluated peri-
anesthetic serum fentanyl concentrations with transdermal fentanyl administration.  
Hypothermic anesthetized cats had significantly lower serum fentanyl concentrations 
compared to normothermic anesthetized cats, although concentrations remained within the 
range believed to confer analgesia (Pettifer and Hosgood, 2003).  Similar findings are 
reported in dogs (Pettifer and Hosgood, 2004).    The impact of alterations in fentanyl 
concentrations on intra-operative analgesia and any anesthetic sparing effects of fentanyl is 
undetermined.  
2.10 Evaluation of Analgesia during General Anesthesia 
Recent investigations have documented a decrease in the serum fentanyl 
concentrations  in hypothermic dogs and cats compared to normothermic dogs and cats 
during inhalant anesthesia in the presence of transdermal fentanyl (Pettifer and Hosgood, 
2003; Pettifer and Hosgood 2004).  Whether the decreased fentanyl concentration alters 
inhalant requirements during anesthesia is not known.  Investigation to assess alterations in 
inhalant anesthetic requirements would require determination of the minimum alveolar 
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concentration (MAC) of the inhalant and comparison to the MAC in hypothermic and 
normothermic animals receiving transdermal fentanyl. 
2.11 Minimum Alveolar Concentration 
The concept of minimum alveolar concentration (MAC) was originally described in 
1963 by Merkel and Eger to provide a repeatable method of measuring and comparing 
anesthetic potencies.  MAC was originally defined as the minimal alveolar concentration of 
inhalant in the alveoli required to prevent a dog from responding to a painful stimulus.  
Subsequently MAC for people was defined as the point at which 50 per cent of the patients 
moved in response to a skin incision (Saidman and Eger, 1964).   Determination of MAC 
requires measuring the end tidal concentration of inhalant which is considered representative 
of the alveolar concentration.  When an anesthetic gas is inhaled it will diffuse down its 
concentration gradient from the alveoli into the arterial blood and then across the blood brain 
barrier until equilibrium is established.  Once equilibrium is established, the end tidal 
concentration of inhalant should equal the concentration of the inhalant in the brain. 
2.11.1 Determination of the Minimum Alveolar Concentration of an Anesthetic   
Two models are used to determine MAC.  The first is the quantal study design used 
in people.  In this model, each person is exposed to a constant anesthetic concentration for a 
set time determined by the inhalant being investigated prior to application of a noxious 
stimulus such as skin incision.  Presence or absence of movement is noted.  The resulting 
quantal information (presence or absence of movement for each person at the different 
inhalant concentrations) is then fit to either a logistic or sigmoid Emax equation and MAC is 
calculated (Sonner, 2002).  The second model employs a bracketing technique.  This method 
is often used in animal experiments.  An animal is exposed to a constant anesthetic 
concentration, a noxious stimulus is applied, and the presence or absence of movement is 
noted.  If an animal moves at the observed concentration, the anesthetic concentration is 
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incrementally increased and the procedure repeated until no movement occurs.  The MAC is 
then determined to be the value midway between the concentration at which movement 
occurred and the concentration at which no movement occurred. 
The noxious stimulus used should be reproducible, and provoke a predictable 
movement.  If the stimulus cannot be measured, it should be supramaximal to avoid any 
variation in response attributable to variation in stimulus. End tidal inhalant anesthetic 
concentration is measured and considered equivalent to the anesthetic concentration in the 
brain.   
2.11.2 Supramaximal Stimulation 
All MAC studies are conducted using supramaximal stimulation.  Supramaximal 
stimulation refers to the point beyond which increasing stimulus intensity will not increase 
MAC (Quasha et al. 1980).  In people the noxious stimuli used is surgical skin incision.  The 
supramaximal stimulation most commonly used in animals is clamping the tail with a 
hemostat i.e. forcep for 30 to 60 seconds.  Electrical stimulation of the limbs, cheek or 
sensitive mucosa has also been used (30-50 V at 50cycles/second for 10 milliseconds).  A 
study comparing electrical stimulation versus tail clamp in rats concluded that electrical 
stimulation provided an equivalent stimulus (Laster et al. 1993).  Several types of 
supramaximal stimuli have been validated in dogs and rabbits including tail clamp and 
electrical stimulation (Valverde et al. 2003). 
2.11.3 Determination of MAC in Dogs 
Following induction of anesthesia, the dog is allowed to stabilize at a chosen end tidal 
gas concentration held constant for 15 minutes.  Fifteen minutes for equilibration is based on 
the assumption that there is a cerebral blood flow of 50ml/100g/minute (Kety and Schmidt, 
1945) and a brain:blood  partition coefficient of 2.5 or less.  If these assumptions are met, 
then 15 minutes allows for at least 95 per cent equilibration between arterial and brain 
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tensions of the agent (Eger et al. 1965).  The end-tidal inhalant concentration is noted and a 
supramaximal stimulus applied.  The dog is observed for any gross purposeful movement i.e. 
movement of the head or trunk.   Swallowing, coughing, or chewing motions are not 
considered purposeful movement since they may be reflex responses not requiring 
consciousness.  If no movement occurs, the inhalant is decreased to 80 or 90 percent of the 
original concentration and 15 minutes is allowed for gas equilibration before reapplying the 
stimulus.  If movement occurs at this lower concentration, the concentration is increased in 
forward and backward increments and stimulation is repeated until the observer can narrow 
the range between the concentration at which occurs and the concentration at which there is 
no movement.  The MAC is taken as the mid point between these two concentrations.  If, on 
the initial stimulation, there is movement, the inhalant concentration is increased by 10 to 20 
% and the process repeated as before until no movement is observed.  The smaller the 
incremental increase and decreases, the more accurate the determination of MAC will be.  
Although MAC is considered a characteristic of the inhalant, many drugs and other factors 
can impact MAC (Table 2), (Stanski et al. 2000; Quasha et al. 1980).  
 2.12 Thermoregulation 
 Body temperature is a function of heat production and loss.  Heat is produced in the 
body as a by-product of metabolism, however heat is continuously being lost to the 
environment.  Body temperature in mammals shows a circadian variation corresponding to 
decreased activity and reduced metabolic rate during sleep.  Control of body temperature 
(thermoregulation) occurs via feedback through the nervous system to the preoptic nucleus 
of the anterior hypothalamus (Sessler et al. 2000).  A decrease in body temperature causes 
stimulation of the posterior hypothalamic sympathetic centers with a resulting increase in 
circulating nor epinephrine resulting in vasoconstriction of cutaneous blood vessels, thereby 
decreasing the amount of heat lost from the skin surface. Other heat sensing areas are also  
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Table 2. Factors that affect minimum alveolar concentration 
 





















No effect Duration of anesthesia 
Sex 







present in the midbrain, brainstem, spinal cord, skeletal muscles, and abdominal organs 
which also play a role in immediate responses to alteration in temperature (Imrie and Hall, 
1990).   
2.13 Effect of General Anesthesia on Thermoregulation   
During the first hour of anesthesia the average person will have a 1-1.5°C drop in 
core body temperature, with a further decrease of 1 - 1.5°C over the next one to two hours, 
followed by a stabilizing of the temperature (Sessler, 1997)   The initial decrease in body 
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temperature is referred to as the redistribution phase, the second decrease as the linear phase, 
and the stable period as the core body temperature plateau. (Figure 4)  
Upon initiation of general anesthesia, peripheral vasodilation allows the core body heat to 
move down a temperature gradient to more peripheral tissues.  This is not a loss of heat, but 
a redistribution of heat resulting in a decrease in core body temperature.  Redistribution 
accounts for up to 80% of the initial decrease in core body temperature during the first hour 
of anesthesia.  The second phase is a slow linear decrease in core temperature which is the 
result of heat loss in excess of heat production.   Heat loss during the linear phase occurs via 






Figure 4.  Decrease in temperature during general anesthesia 
 
The final plateau phase occurs after two to three hours of anesthesia and is 
characterized by a constant core body temperature.  The plateau is described as either 1. 
Passive or 2. Active.  1. The passive plateau occurs when metabolic heat production equals 
heat loss; this is rarely the case in a normothermic anesthetized animal since heat production 
is decreased, while loss is increased.  2. An active plateau occurs when a thermoregulatory 
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response is triggered which causes vasoconstriction.  In people, a core body temperature of 
33 to 35°C is necessary for activation of this response (Sessler, 2000).    
2.13.1 Influence of Temperature on MAC 
Hypothermia is common in subjects undergoing anesthesia and surgery.  This is due 
to a cool operating room environment, exposure of body cavities, and the impairment of the 
thermoregulatory control by the anesthetic agent.   
The effect of hypothermia in reducing anesthesia requirements has been studied 
extensively.  The average change in isoflurane requirements for each 1°C decrease in 
temperature is between 2-6 percent of MAC in dogs (Quasha et al. 1980).   
There is limited information on the effect of transdermal fentanyl and hypothermia 
on anesthetic inhalant requirements in cats and dogs.  Yackey et al. found that there was a 
statistically significant reduction in MAC cats with a transdermal fentanyl.  This study also 
noted that serum fentanyl concentrations peaked during the MAC study, possibly due to the 
use of external warming devices, or changes in peripheral circulation which occur with 
inhalant anesthesia (Yackey et al. 2004).   In order to appreciate the alterations which occur 
in the peripheral circulation associated with inhalant anesthetics, a review of the normal 
determinants of tissue blood flow and how blood flow to the tissues is controlled is useful. 
 Tissue blood flow is determined by blood pressure and the resistance in the 
vessels of the tissue.  The relationship between pressure and resistance can be expressed by 
Ohm’s law, in which blood flow (amperes) is directly proportional to the pressure difference 
across two points (voltage) and inversely proportional to resistance. (Figure 5)  It should be 
noted that resistance to blood flow cannot be measured directly but is calculated from the 




                    Pressure Difference Between 
                   Two points (∆P) 
                           Blood Flow   =     ---------------------------------------- 
(Q)                          Resistance to Flow (R) 
 
 
∆P = Q x R 
R = ∆P / Q 
 
Figure  5. The relationship between blood flow (Q), pressure differential (∆P), and 
resistance to flow (R) can be expressed by Ohm’s law. 
2.14 Autoregulation of Blood Flow  
 Acute autoregulation allows a specific tissue to maintain a relatively constant blood 
flow over a wide range of mean arterial pressures.  The response occurs within 60 to 120 
seconds in response to sudden changes in pressure.   
 Two theories have been proposed to explain how autoregulation occurs.  The 
metabolic theory describes an increase in mean arterial blood pressure increasing blood flow 
and the delivery of nutrients etc.; vasodilatory substances (such as endothelin-derived 
relaxing factor) are flushed out.  These conditions result in blood vessels constricting.  
Conversely, a decrease in blood pressure decreases blood flow and therefore the delivery of 
nutrients and vasodilating substances remain, thus vasodilation occurs.  The myogenic 
theory describes increases in blood pressure resulting in sudden stretch of small blood 
vessels, which in turn causes the smooth muscle of the vessel walls to contract thereby 
reducing the flow back towards normal. 
2.15 Effects of Hypothermia on Tissue Blood Flow 
 Thermoregulatory vasoconstriction occurs when integrated thermal inputs from the 
skin surface, neuroaxis and deep tissues reach a threshold of activation.  In the non-
anesthetized subject, physiologic responses to external cold include vasoconstriction, 
shivering, nonshivering thermogenesis, and piloerection.  Anesthetic agents interfere with 
normal physiologic responses such as vasoconstriction by depressing the central threshold 
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for peripheral vasoconstriction.  Isoflurane decreases the threshold by 3ºC per percent end-
tidal volume of anesthetic (Støen et al. 1990).  By promotion of peripheral vasodilation (as 
opposed to the expected vasoconstriction) heat loss is increased.  At a core body temperature 
of about 34.5ºC and in the absence of ongoing active cooling, vasoconstriction occurs 
(mainly of the hands and feet in people).  This vasoconstriction decreases ongoing heat loss 
by approximately 25 % and results in a temperature plateau being established (Sessler et al. 
1990).  The increase in peripheral vasodilation could result in decreased amounts of fentanyl 
being absorbed from a transdermal patch which could in turn reduce the availability of 
fentanyl at the biophase. 
2.16 Effects of Isoflurane on Tissue Blood Flow 
 Inhaled anesthetics produce marked changes in cardiovascular function including 
changes in heart rate, myocardial contractility, cardiac output, and systemic vascular 
resistance.  Peripheral circulatory effects are dose dependant and specific for each anesthetic.  
Isoflurane increases heart rate and decreases systemic vascular resistance when administered 
to healthy people (Cahalan et al. 1987).  Decreases in systemic vascular resistance during 
administration of isoflurane principally reflect substantial increases in skeletal muscle blood 
flow (Stevens et al. 1971).  Cutaneous blood flow is also increased by isoflurane.  
Implications of these alterations in blood flow may include wasted perfusion relative to 
oxygen needs, enhanced delivery of drugs to the neuromuscular junction, enhanced uptake of 
drugs administered transdermally, and the loss of body heat and development of mild to 
moderate hypothermia due to increased cutaneous blood flow. 
2.17 Transdermal Fentanyl Concentrations during Anesthesia 
Transdermal fentanyl is an option for the perioperative management of many species 
including cats and dogs.  Intra-anesthesia hypothermia has been documented to decrease 
fentanyl concentrations.  Any change in the anesthetic sparing effect of transdermal fentanyl 
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during anesthesia has not been evaluated in dogs.  If reductions in serum fentanyl 
concentrations are the result of decreased uptake of fentanyl from the dermal depots, then 
anesthetic sparing effect of fentanyl will be lessened.  However, if reductions in fentanyl 
concentrations are due to a shift of the drug into the biophase, then any anesthetic sparing 
effect should be maintained. 
2.18 Hypothesis and Objectives for Study 
 The objectives of this investigation were to determine: (i) if the minimum alveolar 
concentration of isoflurane would be different between normothermic compared with 
hypothermic dogs with transdermal fentanyl; (ii) the magnitude of any change in isoflurane 
requirements during moderate hypothermia; (iii) if there was any interaction between the 
effects of body temperature and transdermally administered fentanyl on the minimum 
alveolar concentration of isoflurane in dogs.  We hypothesized that the MAC of isoflurane 
would be lower in normothermic dogs with transdermal fentanyl and hypothermic dogs 
when compared to normothermic dogs with no TDF.  In addition we also hypothesized the 
MAC for hypothermic dogs receiving transdermally administered fentanyl would not be 





























This investigation was approved by the Institutional Animal Care and Use 
Committee, Louisiana State University.  Six healthy mixed breed dogs (2 males, 4 females) 
with a mean ± SD weight of 26.0 ± 3.54 kg were used.  Normal health status was described 
by a general physical examination, complete blood count and biochemical profile performed 
prior to the investigation.  The dogs were housed in a climate controlled building 
(temperature range 70 - 80 °F) with light provided between 6 am and 6pm.  The dogs were 
fed a commercially available dog food (Prolab Canine 1600, PMI Feed Inc., St Louis, MO 
63144) ad libitum.   
 All dogs received 4 treatments in random order: 1. sham patch- normothermia
 (C-NORM), 2. sham patch-hypothermia (C-HYPO), 3. fentanyl patch-normothermia 
(F-NORM), 4. fentanyl patch-hypothermia (F-HYPO).  Random order was determined for 
each dog by drawing the treatment order from a hat.  There was a minimum of 14 days 
between each trial. 
 Twenty-four hours prior to anesthesia induction, either a sham patch or a 75µg/hr 
fentanyl patch (Duragesic, Janssen Pharmaceutica Products, L.P., Titusville, NJ 08560) was 
applied to the lateral thorax of the dog.  The initial side for patch placement was determined 
by a coin toss.  Subsequent placements were made on alternate sides.  The area for patch 
placement was carefully clipped free of hair without abrading the skin.  The clipped area 
was brushed clean, but not scrubbed.  The patch was placed on the clipped area, held in 
place for one minute to ensure adhesion and then covered with elastic tape (Elastikon, 
Johnson and Johnson, Arlington, TX 76004).  The elastic tape was covered with a single 
layer of bandaging tape (Vetwrap, 3M, St. Paul, MN 55144).  The patches remained in 
place until the end of each trial. 
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3.2 Anesthesia and Instrumentation  
 All dogs had food, but not water withheld for 12 hours prior to the induction of 
anesthesia.  The induction of anesthesia occurred at the same time each day for each dog to 
avoid any influence of MAC alterations associated with circadian patterns.  Anesthesia was 
induced by facemask with isoflurane (Isoflo, Abbott Laboratories, North Chicago, IL 
60064) in 100 percent oxygen.  Following induction, the trachea was intubated with an 
appropriately sized endotracheal tube and the dogs were connected to a rebreathing circle 
system with a fresh gas flow of 30ml/kg/min.  The dogs were immediately placed on 
intermittent positive pressure ventilation (SurgiVet ParaPAC ventilator, SurgiVet Inc., 
Waukesha, WI 53186), with rate and tidal volume adjusted to maintain normocapnea 
(ETCO2 of 32 - 42 mmHg).  Initial isoflurane vaporizer settings were 1.5 - 2%.   
 Immediately following the induction of anesthesia, a 20 gauge, 3.2 cm catheter 
(Abbocath -T, Abbott Ireland, Sligo, Republic of Ireland) was placed in a cephalic vein for 
the administration of a balanced electrolyte solution (Normosol-R, Abbott Laboratories, 
North Chicago, IL 60064) at 5ml/kg/hr for the duration of anesthesia.  An 18 gauge, 28 cm 
through the needle catheter (Venocath - 16, Abbott Ireland, Sligo, Republic of Ireland) was 
placed in the jugular vein for obtaining venous samples for fentanyl analysis.  The jugular 
catheters were placed only when dogs were receiving fentanyl transdermally.  The catheter 
was placed in the jugular vein opposite the side on which the patch was located.  A 22 
gauge, 3.2 cm catheter was placed in the dorsal pedal artery.  A pressure transducer was 
connected to the catheter with non-compliant tubing for direct arterial pressure 
measurement.  A multi-function monitor (Biochem International 9100 Multigas Monitor, 
BCI, Waukesha, WI 53188) was used.  The arterial catheter was also used to obtain samples 
for blood gas and acid-base analysis.  Inspired and end-tidal inhalant concentration 
(ETINHAL) and the partial pressure of CO2 in the expired gas (ETCO2) were measured with a 
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sidestream analyzer (Biochem International 9100 Multigas Monitor, BCI, Waukesha, WI 
53188).  External calibration of the monitor and verification of isoflurane and carbon 
dioxide determinations was performed prior to and after each trial (Anesthesia Calibration 
Gas, Criticare Systems Inc., Waukesha, WI 53186). A standard lead II ECG, esophageal 
temperature and oxygen saturation (SpO2) (Biochem International 9100 Multigas Monitor, 
BCI, Waukesha, WI 53188) were monitored during anesthesia. 
3.3 Data Collection 
 Heart rate (HR), respiratory rate (RR), and rectal temperature were recorded 
immediately prior to the induction of anesthesia.  The HR, RR, esophageal temperature 
(TEMP), ETCO2, SPO2, ETINHAL, systolic blood pressure (SBP), diastolic blood pressure 
(DBP), and mean blood pressure (MBP) were recorded at 15 minutes and 30 minutes 
following induction, and prior to the application of each electrical stimulation.  The HR, 
RR, and rectal temperature were also recorded at 15, 30 and 90 minutes following the end 
of the anesthetic period. 
 Samples for arterial blood gas and acid base analysis (pH, PaO2, PaCO2, HCO3, ABE) 
were drawn immediately prior to application of the first electrical stimulus, and following 
the last application of electrical stimulus.  Samples were drawn into 1 ml heparinized plastic 
syringes and analyzed immediately (IRMA Series 2000 Blood Analysis System, Diametrics 
Medical Inc., St. Paul, MN 55113).  The values obtained with the IRMA were compared 
with results from the clinical pathology laboratory at Louisiana State University and the 
results were consistently similar.  Internal self calibration of the blood gas analysis system 
was carried out prior to each sample analysis. 
3.4 Body Temperature 
 During the C-NORM and F-NORM treatments, the dogs were kept warm with 
thermostatically controlled circulating hot water blankets and covered with towels.  The 
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dogs were maintained at a TEMP within 1°C of the baseline TEMP recorded prior to the 
induction of anesthesia.  
 During the C-HYPO and F-HYPO treatments, immediately after induction, the dogs 
were actively cooled to a TEMP of 34 to 35°C by placing towel wrapped ice packs in the 
inguinal and axillary regions.  The target temperature for the HYPO treatment was chosen 
because it reflected the degree of hypothermia expected in animals during routine anesthesia 
and surgery that do not receive aggressive heat supplementation.  Target temperatures for 
all treatments were held constant for one hour prior to the beginning of the first MAC 
determination.   
 Animal were placed in lateral recumbency with the sham or fentanyl patch on the 
dependent side.  Care was taken to ensure that the patches did not come in contact with the 
circulating water blankets or ice packs.  There was no attempt to rewarm hypothermic 
animals in the post anesthetic period. 
3.5 Determination of Minimum Alveolar Concentration 
 Two 22 gauge needle electrodes connected to an electrical stimulator (Grass S88 
Stimulator, Astro-med Inc., West Warwick, RI 02893) were inserted 4 cm apart in the 
buccal mucosa of the lower jaw.  Electrical stimulation was delivered at 50 cycles per 
second, 6.5 milliseconds duration, at 40 volts (Eger et al. 1965, Valverde et al. 2003).  
Stimulator output was verified with a voltmeter prior to each trial.   
   During MAC determinations, a positive response was defined as gross purposeful 
movement of the head, trunk, or extremities.  Licking, chewing, and swallowing were not 
considered purposeful (Eger et al. 1965).  If no movement occurred after stimulation, the 
inhalant concentration was decreased by 20 percent and held constant for 15 minutes to 
allow for inhalant equilibration.  The stimulation was then repeated.  This process continued 
until a movement was elicited. Once movement was elicited, the inhalant concentration was 
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increased by 10 percent and held constant for 15 minutes to allow for inhalant equilibration.  
Stimulation was repeated. The MAC was considered be the inhalant concentration midway 
between the highest concentration at which movement was elicited and the lowest 
concentration at which no movement occurred.  The differences between the mean MAC 
values for the normothermic dogs with and without TDF were calculated by adding the 
MAC values for each dog in each group and determining the mean.  The mean percentage 
difference between the normothermic group without fentanyl and with fentanyl was then 
determined by averaging the difference between the MAC values for each dog in each 
group. 
3.6 Fentanyl Concentration Determination 
 Venous blood samples for determination of fentanyl concentrations were drawn prior 
to patch application, prior to the induction of anesthesia, and 15 minutes post anesthesia.  
For F-NORM and F-HYPO treatments 3ml samples were drawn from the jugular catheter 
immediately prior to each application of electrical stimuli and at 30 and 90 minutes after 
discontinuing anesthesia.  For C-NORM and C-HYPO treatments, samples were drawn 
prior to the induction of anesthesia and at 30 minutes after discontinuing anesthesia to 
confirm the absence of any fentanyl in these treatments.  Each blood sample was placed in a 
serum tube, cooled and then centrifuged to harvest the serum.  The serum was stored at -
70°C until the fentanyl concentration determination was performed.   
 Fentanyl concentration determination was performed by radioimmunoassay (Coat-A-
Count® Fentanyl, Diagnostic Products Corporation, Los Angeles CA 90045).  Measurement 
of serum fentanyl concentrations using a radioimmunoassay (RIA) has previously been 
found to result in overestimation of the serum concentrations by up 29-94% (Schüttler and 
White, 1984).  Overestimation was related to a reduction in binding sites for the labeled 
fentanyl after pre-incubation of the sample and antiserum.  To overcome this problem the 
 42
following steps were followed: 1) the antiserum was added to the sample and labeled drug 
as the final step; 2) calibration curves were performed using the pooled dogs blank serum, 
and finally; 3) each step of the RIA was carried out identically to reduce variability 
(Schüttler and White, 1984).  Once these steps are instituted the comparison of a fentanyl 
RIA with gas-liquid chromatography (GLC) demonstrated the validity of the RIA as an 
accurate measurement technique for fentanyl concentrations.  Spiked samples were 
compared at different fentanyl concentrations and no statistically significant differences in 
the mean values measured by GLC and the RIA were noted (Woestenborghs et al, 1987).  
Gas-liquid chromatography is taken to be the gold standard for evaluating serum 
concentrations of drugs.    
 In this study calibration curves were obtained by obtaining a pool of negative serum 
from the dogs, then spiking the samples with known amounts of fentanyl.  The assay was 
then performed on these samples and results plotted and compared with the standard curve 
for the Coat-A-Count fentanyl assay with adjustments made for variation.  The interassay 
coefficients of variation over the range of concentrations of 0.25, 0.5, 1.0, 2.5, and 4.0 
ng/ml-1 was 5.7, 9.8, 2.3, 5.2, and 8.8 % respectively (n=20).  The intra assay coefficients of 
variation for these same concentrations were 5.4, 9.5, 2.3, 5.4, and 9.3 %, respectively.  
Values less than 10 % are considered acceptable for both intra and interassay coefficients of 
variation (Schuttler et al, 1984).  The RIA is very specific for fentanyl and has no cross 
reactions with metabolites of fentanyl.  All samples in this study were assayed in duplicate.  
The limit of detection of this assay was 0.08ng/ml-1 but the proven level of quantification 
for the assay was 0.10 ng/ml-1.  The fentanyl RIA has been used in numerous fentanyl 
studies in animals (Kyles et al, 1996; Wilkinson et al, 2001; Foley et al, 2001; Carroll et al, 
1999; Egger et al, 2003; Pettifer and Hosgood, 2003; Pettifer and Hosgood, 2004). 
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3.7 Statistical Analysis 
• Sample Size Assessment 
 With a complete randomized block design, (blocked by dog), the intra-dog variation is 
estimated to be small (SD ~ 10%).  The effect of inter-dog variation is minimized by the 
design and the analysis such that all dogs receive all treatments.  With an expected 
difference of at least 50% of MAC between the treated and untreated control and the most 
severe treatment protocol (hypothermia and fentanyl), using a sample size of n = 6 and 
setting α at 0.05, the power was 100%, implying certainty that this magnitude of difference 
would be detected.  The minimal difference in MAC values between treatments detected 
with these criteria with at least 80% power was approximately 20 %.  Had the difference 
between the treatments been as low as 10%, the power of the investigation would have been 
reduced to 50%, thus there would have been only a 50% likelihood that this difference (if 
real) would have been detected.  By increasing α to 0.1, the power could be increased to 
100%.  The investigators believed that the consequence of increasing alpha to 0.1, and thus 
increasing the risk of concluding a difference when there is not one, would not seriously 
impact animals’ health and hence obviates unnecessarily increasing sample size (the sample 
size would have to have been increased to 13 for 90% power and to 28 for 100% power). 
• Statistical Analysis 
 All results are expressed as mean ± SEM, and differences were considered 
significant when p ≤ 0.05.  PROC UNIVARIATE, PROC MIXED, and PROC GLM (SAS 
v9.0, SAS Institute, Cary, NC) was used for the analysis.   
The MAC was evaluated for normality using the Shapiro-Wilk statistic with the null 
hypothesis of normality rejected at p ≤ 0.05.  Effect of protocol on MAC was assessed using 
a mixed effect linear model that included the fixed effect of protocol (4 levels) and the 
random variance of each dog.  The repeated protocols on each dog were also accounted for 
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in the model.  If a significant effect of protocol on MAC at p ≤ 0.05 was determined then 
comparisons between protocols were made using least means squares with a Scheffe 
adjustment to maintain α at 0.05. 
For the purpose of describing the four protocols, comparisons were made between 
protocols for heart rate, mean arterial blood pressure, and body temperature at the time of 
MAC determination.  These variables were considered continuous and were normally 
distributed with failure to reject the null hypothesis of normality at p ≤ 0.05 using the 
Shapiro-Wilk statistic.  A repeated measures ANOVA was used to evaluate the hear rate, 
mean arterial blood pressure, and temperature.  Where significant effect of treatment at p≤ 
0.05 was found, comparisons were made with the Scheffe adjustment to maintain alpha at 
0.05. 
The PAUC was compared for C-FENT and H-FENT.  The PAUC was considered to 
be continuous and normally distributed with failure to reject the null hypothesis of normality 
at p≤ 0.05 using the Shapiro-Wilk statistic.  A paired t-test was used with significance 







































The mean (± SEM) MAC for the C-NORM treatment (1.20 ± 0.17 %) was 
significantly higher (p < 0.05) than the MAC for the C-HYPO treatment (0.89 ± 0.18 %), the 
F-NORM treatment (0.76 ± 0.10 %), and the F-HYPO treatment (0.81 ± 0.17 %). ( Figure 3)  
There was no significant difference between the MAC values for the C- HYPO, F-NORM, 
and F-HYPO treatments.  The mean reduction in isoflurane in F-NORM compared to C-
NORM was 36.6% ± 0.47%.  
 























Figure 6.  Mean (± SEM) Minimum Alveolar Concentration (%) for isoflurane C-
NORM (control normothermia), C-HYPO (control hypothermia), F-NORM (fentanyl 
normothermia), and F-HYPO (fentanyl hypothermia).  Means with different superscripts 
are significantly different (p ≤ 0.05)  
Heart rate and mean arterial blood pressure determined at the time of MAC 
determination were not significantly different between treatments.   The mean TEMP in 
normothermic dogs (37.45 ± 0.06 °C) was significantly lower than that of hypothermic dogs 
(34.45 ± 0.09 °C).   
There was no detectable fentanyl in control dogs.  The mean fentanyl PAUC for F-




Normothermic dogs receiving transdermal fentanyl had a mean reduction in 
isoflurane MAC of 36.6 % compared to normothermic dogs without transdermal fentanyl.  
In a similar study in cats, there was a significant reduction in MAC of between 17.8 % and 
18.1 % depending on the size of the patch applied (25 or 50 mcg/hr) compared to 
normothermic cats without transdermal fentanyl (Yackey et al. 2004).  A 65 % reduction in 
the MAC of enflurane anesthetized dogs receiving intravenous fentanyl has been reported 
(Murphy and Hug, 1982).  In these dogs high serum fentanyl concentrations of 25-30 ng/ml 
were recorded (Murphy and Hug, 1982).  In our study, serum fentanyl concentrations were 
on average, below 2 ng/ml, possibly accounting for the smaller reduction in MAC.   
Different inhaled anesthetics have different effects on cardiovascular function, 
specifically dermal perfusion, which could alter the serum concentrations of fentanyl during 
transdermal administration.  An investigation of serum fentanyl concentrations in dogs 
receiving transdermal fentanyl and anesthetized with either halothane or isoflurane described 
an effect of inhalant on the magnitude of reduction (Pettifer and Hosgood, 2004).      
 In the present investigation, the MAC reduction in hypothermic isoflurane 
anesthetized dogs was consistent with previous work that demonstrated a decrease of 2-6 % 
in isoflurane MAC for every 1°C decrease in temperature in dogs (Quasha et al. 1980).  The 
MAC reduction produced by hypothermia during anesthesia with different inhalants is not 
uniform.  For a 10 ºC decrease in temperature there is a 50 % decrease in MAC for halothane 
whereas cyclopropane MAC decreases only 25 %.  The less oil soluble inhalants 
demonstrate smaller reductions in MAC, while the more lipid soluble inhaled anesthetics 
have greater reductions (Quasha et al, 1980).  The gas phase potency of inhaled anesthetics 
increase with decreasing temperature.  There is an associated increase in anesthetic solubility 
with a decrease in temperature so that the aqueous phase potencies remain relatively 
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constant, but this will vary depending on the solubility of the inhalant (Franks and Lieb, 
1996).  In the current investigation hypothermic animals demonstrated a 3°C temperature 
decrease, suggesting a maximum decrease in MAC of up to 18 %.  The difference between 
18% and the observed 25 % amounts to a very small difference in vaporizer setting (0.084 
%) and is of little clinical relevance. 
 The difference in MAC reduction between the normothermic and hypothermic TDF 
groups and the hypothermic sham patched group were not statistically significant.  This 
observation implies that no additional sparing effect or analgesia was provided by the 
transdermal fentanyl in hypothermic animals.  If the transdermal fentanyl were providing 
analgesia in the hypothermic group a greater reduction in MAC would be expected.  The 
lack of anesthetic sparing effect of transdermally administered fentanyl in this investigation 
could be the result of a significant reduction in uptake of fentanyl from the dermal depots 
during hypothermia.  
 The AUC was evaluated for each of the fentanyl groups, but due to variations in the 
time taken to complete each MAC study, we also evaluated the PAUC for the one hour 
period immediately preceding the final MAC determination to standardize the time included 
in the AUC assessment of fentanyl concentration.  It was decided that this would be more 
reflective of the actual fentanyl concentrations responsible for the MAC determination 
compared to evaluating the area under the curve for the entire duration of the study which 
was variable from animal to animal and treatment to treatment.  The AUC and PAUC were 
not significantly different between F-HYPO and F-NORM.  Considerable inter- and intra-
individual variations in serum fentanyl concentrations achieved during transdermal 
administration may have obscured any chance of detecting a real difference.  As an example, 
one dog in the hypothermia group had detectable serum fentanyl concentrations prior to 
induction of anesthesia but had undetectable levels for the duration of the study.  Serum 
 49
fentanyl concentrations returned to pre-anesthesia levels in this animal at the conclusion of 
the MAC determination study.  Such marked variability in serum fentanyl concentrations 
decreases the likelihood of detecting any real difference between treatment groups.  Given 
the variability in PAUC observed in the current investigation, a sample size of 20 would be 
required to determine a difference with 80% power.  When determining the sample size for 
this study we did not include the PAUC in our considerations but rather focused on the 
sample size needed to identify differences in the MAC values.  Because of the extreme 
variability in the study a p value ≤ 0.05 resulted in 18% power with the sample size of 6.  
With sample size unchanged and p ≤ 0.2 power would increase to 44% but still remain 
below an acceptable level.  Thus increasing sample size is likely to have the most impact on 
better defining this result. 
A possible explanation for lack of a detectable difference in effect (MAC) between 
hypothermic dogs receiving transdermally administered fentanyl and those not is that a shift 
out of the biophase for fentanyl may have occurred.  In this case changes in PAUC may not 
have been noted but there would be a decreased efficacy of the fentanyl. 
A three compartment model is used to describe distribution of fentanyl in the body.  
The three compartments are the plasma in the extracellular space, the interstitial fluid in the 
extracellular space and the cellular space (Bentley et al, 1982; McClain and Hug, 1980; Fung 
and Eisele, 1980; Schleimer et al, 1978).  Under normal body conditions approximately 10 
% of the fentanyl dose is present in the extracellular fluid including the vascular space and 
approximately 90 % is present intracellularly (Bailey et al, 2000).  Equilibrium between 
ionized fentanyl, the free base, and the fentanyl molecules bound to macromolecules exists 
(Bailey et al, 2000).  The concentration of ionized fentanyl in the interstitial fluid (or 
biophase) determines the pharmacologic effect, because the opioid receptors are located at 
the cell surface.   A small decrease in extracellular pH shifts the equilibrium toward higher 
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ionized fentanyl and results in more base fentanyl being released from the cell in an attempt 
to re-establish the equilibrium.  The resulting change in equilibrium and increase in ionized 
fentanyl in the interstitial fluid results in enhancement of pharmacologic effect (Bailey et al, 
2000).  This would initially result in no alteration in serum fentanyl concentration as the shift 
is from the intracellular base fentanyl to the ionized fentanyl.  Eventually a decrease in 
serum concentrations would be noted as equilibrium was re-established.  In this study no 
decrease in plasma levels were noted nor was there any increase in the reduction of MAC 
compared to hypothermic dogs with no transdermal fentanyl.   
 In summary, the use of transdermal fentanyl in normothermic dogs did result in a 
significant reduction in the MAC for isoflurane.  Transdermal fentanyl did not alter the 
MAC for isoflurane in hypothermic dogs.  Further investigation of the PAUC with an 
appropriate sample size would be needed to fully evaluate the impact of hypothermia on 
intra-anesthesia fentanyl concentrations.   
It is recommended that animals with transdermal fentanyl patches in place should be 
maintained within a normothermic temperature range in order for transdermal fentanyl to be 
effective.   
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Dog TX Time Fent Temp HR RR Systolic Diastolic Mean 
9048 1 0 0 38.8 80 20 . . .
9048 1 15 . 37.8 110 14 . . .
9048 1 30 . 37.6 101 14 120 71 85
9048 1 MAC1 . 37.2 97 14 115 63 76
9048 1 MAC2 . 37.3 110 15 140 81 96
9048 1 MAC3 . 37.2 87 14 127 69 86
9048 1 p15 0 38 80 16 . . .
9048 2 0 0 37.2 108 14 . . .
9048 2 15 . 36.4 112 12 . . .
9048 2 30 . 36 88 12 126 72 89
9048 2 MAC1 . 34.1 85 11 104 59 74
9048 2 MAC2 . 34.2 160 30 140 91 110
9048 2 MAC3 . 34.5 140 26 122 71 90
9048 2 p15 0 36.2 100 10 . . .
9048 3 0 0.896 38 56 12 . . .
9048 3 15 0.601 37.2 85 10 . . .
9048 3 30 0.584 36.8 81 10 96 51 66
9048 3 MAC1 1.569 36.9 84 10 82 43 54
9048 3 MAC2 1.341 37 80 10 92 50 64
9048 3 MAC3 1.412 37.1 68 10 99 48 65
9048 3 MAC4 1.287 37.2 61 10 99 46 63
9048 3 MAC5 1.677 37.3 56 10 90 45 58
9048 3 MAC6 1.192 37.3 59 10 9 43 61
9048 3 p15 1.31 37.5 64 8 . . .
9048 3 p30 0.934 37.7 68 8 . . .
9048 3 p90 1.034 38 60 12 . . .
9048 4 0 0.383 38.1 72 16 . . .
9048 4 15 0.682 37.3 80 8 101 51 64
9048 4 30 0.505 35.9 73 8 83 46 57
9048 4 MAC1 0.621 34.2 69 8 105 53 68
9048 4 MAC2 0.461 34.3 63 8 107 49 78
9048 4 MAC3 0.68 34.2 51 8 137 69 87
9048 4 MAC4 0.578 34.2 50 8 156 75 100
9048 4 MAC5 0.662 34.4 49 8 151 62 83
9048 4 MAC6 0.611 34.2 49 8 159 63 97
9048 4 p15 0.627 34.8 200 20 . . .
9048 4 p30 0.656 35.9 140 20 . . .











Dog TX Time Fent Temp HR RR Systolic Diastolic Mean 
9053 1 0 0 38.7 96 20 . . .
9053 1 15 . 38.2 112 16 . . .
9053 1 30 . 38 110 17 82 54 64
9053 1 MAC1 . 37.3 119 13 92 54 70
9053 1 MAC2 . 37.3 121 13 92 58 72
9053 1 MAC3 . 37.2 120 13 100 66 77
9053 1 p15 0 37.4 100 16 . . .
9053 2 0 0 38.4 80 12 . . .
9053 2 15 . 36.4 125 13 99 42 64
9053 2 30 . 35.6 112 10 71 40 52
9053 2 MAC1 . 34.6 87 8 90 53 64
9053 2 MAC2 . 34.7 110 18 128 75 94
9053 2 MAC3 . 34.7 115 8 126 80 96
9053 2 p15 0 36.5 80 12 . . .
9053 3 0 0.204 38.7 120 12 . . .
9053 3 15 0.112 37 106 10 . . .
9053 3 30 0.193 37.1 92 10 85 50 61
9053 3 MAC1 0.225 37 92 10 84 48 57
9053 3 MAC2 0.22 37.2 97 10 102 61 72
9053 3 MAC3 0.21 37.2 93 10 109 61 74
9053 3 MAC4 0.182 37.2 87 10 113 62 77
9053 3 MAC5 0.227 37.2 98 10 117 65 79
9053 3 MAC6 0.215 37.5 86 10 119 61 76
9053 3 p15 0.278 37.3 100 12 . . .
9053 3 p30 0.468 37.5 92 12 . . .
9053 3 p90 0.633 38.1 124 12 . . .
9053 4 0 0.123 38 104 32 . . .
9053 4 15 0 35.6 124 11 . . .
9053 4 30 0 35.6 124 11 80 48 60
9053 4 MAC1 0 34.4 102 10 78 49 59
9053 4 MAC2 0 34.4 102 10 109 65 78
9053 4 MAC3 0 34.7 91 10 128 80 89
9053 4 MAC4 0 35.2 96 10 116 64 82
9053 4 p15 0.311 35.8 120 24 . . .
9053 4 p30 0.741 36.6 96 16 . . .













Dog TX Time Fent Temp HR RR Systolic Diastolic Mean 
9054 1 0 0 37.6 66 10 . . .
9054 1 15 . 37.3 98 10 . . .
9054 1 30 . 37.1 135 13 99 56 74
9054 1 MAC1 . 37.1 149 12 107 65 83
9054 1 MAC2 . 37.2 78 9 122 78 91
9054 1 MAC3 . 37.5 140 9 113 75 89
9054 1 p15 0 37.3 120 10 . . .
9054 2 0 0 37.9 84 16 . . .
9054 2 15 . 37.2 130 10 . . .
9054 2 30 . 36.3 110 10 113 65 80
9054 2 MAC1 . 34.3 142 10 101 73 56
9054 2 MAC2 . 34.5 126 10 118 89 68
9054 2 MAC3 . 34.4 138 10 123 63 85
9054 2 p15 0 35.2 136 20 . . .
9054 3 0 0.848 37.7 68 20 . . .
9054 3 15 0.974 37.2 68 10 113 56 70
9054 3 30 0.862 36.8 64 10 97 51 66
9054 3 MAC1 0.909 37.1 62 10 114 56 74
9054 3 MAC2 1.008 37.2 64 10 120 65 80
9054 3 MAC3 1.023 37.4 6 10 129 67 85
9054 3 p15 0.951 37.7 112 20 . . .
9054 3 p30 0.903 37.7 120 20 . . .
9054 3 p90 1.26 37.7 84 20 . . .
9054 4 0 0.794 37.5 72 18 . . .
9054 4 15 0.722 36.3 76 14 . . .
9054 4 30 0.687 35.8 75 14 78 47 56
9054 4 MAC1 0.756 34.4 129 16 108 66 81
9054 4 MAC2 0.791 34.2 112 16 135 77 96
9054 4 MAC3 0.688 34.2 96 18 131 67 86
9054 4 p15 0.782 34.2 96 20 . . .
9054 4 p30 0.71 35.4 100 16 . . .















Dog TX Time Fent Temp HR RR Systolic Diastolic Mean 
9011 1 0 0 38.3 80 20 . . .
9011 1 15 . 37.6 94 10 . . .
9011 1 30 . 37.4 87 10 114 56 74
9011 1 MAC1 . 37.4 74 10 121 65 80
9011 1 MAC2 . 37.4 70 10 130 76 91
9011 1 MAC3 . 37.4 56 10 136 70 89
9011 1 MAC4 . 37.3 93 10 117 69 83
9011 1 p15 0 37.2 88 18 . . .
9011 2 0 0 37.2 60 10 . . .
9011 2 15 . 36.1 109 10 . . .
9011 2 30 . 36.2 108 10 94 58 70
9011 2 MAC1 . 34.7 81 10 103 61 76
9011 2 MAC2 . 34.4 70 10 114 72 87
9011 2 MAC3 . 34.4 70 10 128 80 100
9011 2 MAC4 . 34.4 98 10 131 80 100
9011 2 p15 0 35.2 100 12 . . .
9011 3 0 0.807 37.4 60 16 . . .
9011 3 15 1.533 35.9 87 18 . . .
9011 3 30 1.123 35.5 76 19 114 60 76
9011 3 MAC1 1.149 37.4 60 18 115 54 74
9011 3 MAC2 0.846 37.5 63 18 103 51 66
9011 3 MAC3 0.813 37.5 61 18 115 90 96
9011 3 MAC4 0.808 37.5 100 18 106 57 74
9011 3 p15 0.798 37.5 100 20 . . .
9011 3 p30 0.783 37.5 80 16 . . .
9011 3 p90 0.777 37.7 60 16 . . .
9011 4 0 0.629 37.8 72 16 . . .
9011 4 15 0.526 35.1 67 10 . . .
9011 4 30 0.708 34.6 73 10 87 50 63
9011 4 MAC1 0.692 34.3 65 10 67 54 61
9011 4 MAC2 0.739 34.4 59 10 90 54 67
9011 4 MAC3 0.812 34.3 52 10 97 58 74
9011 4 MAC4 0.753 34.2 47 10 104 64 82
9011 4 MAC5 0.676 34.2 40 10 113 61 83
9011 4 MAC6 0.747 34 35 10 120 66 87
9011 4 MAC7 0.841 34.3 35 10 115 70 88
9011 4 p15 0.855 35 128 16 . . .
9011 4 p30 0.926 36 84 16 . . .










Dog TX Time Fent Temp HR RR Systolic Diastolic Mean 
PACC 1 0 0 39 64 52 . . .
PACC 1 15 . 38.9 95 8 60 30 39
PACC 1 30 . 38.4 66 10 123 53 72
PACC 1 MAC1 . 37.6 61 10 127 50 69
PACC 1 MAC2 . 37.5 62 10 121 50 59
PACC 1 MAC3 . 37.5 66 10 118 50 67
PACC 1 p15 0 37.2 72 16 . . .
PACC 2 0 0 38.7 100 20 . . .
PACC 2 15 . 36.8 70 10 . . .
PACC 2 30 . 36 68 10 68 47 57
PACC 2 MAC1 . 34 75 10 77 39 51
PACC 2 MAC2 . 34.3 80 10 107 60 76
PACC 2 MAC3 . 34.3 73 10 111 58 75
PACC 2 MAC4 . 34.3 80 10 120 63 84
PACC 2 MAC5 . 34.3 64 10 125 63 84
PACC 2 MAC6 . 34.4 72 10 121 60 80
PACC 2 MAC7 . 34.4 64 10 120 55 77
PACC 2 p15 0 35.5 140 20 . . .
PACC 3 0 1.607 38.3 80 16 . . .
PACC 3 15 1.127 37.8 58 16 . . .
PACC 3 30 1.499 37.8 65 16 . . .
PACC 3 MAC1 1.727 37.4 34 18 151 45 66
PACC 3 MAC2 1.686 37.2 37 18 139 48 71
PACC 3 MAC3 1.659 37.3 35 18 134 44 61
PACC 3 p15 1.72 37.5 88 24 . . .
PACC 3 p30 1.519 37.9 88 24 . . .
PACC 3 p90 1.389 37.8 66 24 . . .
PACC 4 0 1.003 38 80 10 . . .
PACC 4 15 2.513 37 50 10 . . .
PACC 4 30 2.13 36.6 59 10 85 33 49
PACC 4 MAC1 1.708 34.5 44 10 83 31 45
PACC 4 MAC2 1.64 34.6 52 10 108 48 66
PACC 4 MAC3 1.641 34.3 49 10 108 46 64
PACC 4 p15 1.405 36 80 14 . . .
PACC 4 p30 1.261 36 100 10 . . .












Dog TX Time Fent Temp HR RR Systolic Diastolic Mean 
9041 1 0 0 38.8 96 16 . . .
9041 1 15 . 37.4 100 12 . . .
9041 1 30 . 37.4 89 12 90 54 65
9041 1 MAC1 . 37.3 98 12 94 55 64
9041 1 MAC2 . 37.5 94 12 94 52 64
9041 1 p15 0 37.6 96 12 . . .
9041 2 0 0 38.6 80 16 . . .
9041 2 15 . 37.2 113 17 86 51 63
9041 2 30 . 36.7 110 12 111 66 78
9041 2 MAC1 . 34.2 101 10 89 54 66
9041 2 MAC2 . 34.1 110 10 118 74 88
9041 2 MAC3 . 34.2 120 10 120 70 89
9041 2 MAC4 . 34.5 98 17 149 70 103
9041 2 MAC5 . 34.5 161 17 137 70 90
9041 2 p15 0 35.4 100 20 . . .
9041 3 0 0.611 38.5 72 16 . . .
9041 3 15 0.676 38 118 12 . . .
9041 3 30 0.666 38 107 12 130 63 81
9041 3 MAC1 0.823 37.5 115 17 116 57 76
9041 3 MAC2 0.678 37.6 111 16 120 63 82
9041 3 MAC3 0.739 37.7 116 17 125 71 88
9041 3 MAC4 0.746 37.7 113 16 121 67 85
9041 3 p15 1.051 37.7 128 20 . . .
9041 3 p30 0.972 37.9 136 32 . . .
9041 3 p90 0.904 38.3 116 20 . . .
9041 4 0 0.223 38 88 16 . . .
9041 4 15 0.409 36.9 75 11 . . .
9041 4 30 0.461 35.9 88 11 . . .
9041 4 MAC1 0.334 34.5 143 10 107 53 75
9041 4 MAC2 0.323 34.5 110 10 117 58 76
9041 4 MAC3 0.342 34.5 97 10 120 60 80
9041 4 MAC4 0.274 34.4 88 10 133 60 80
9041 4 p15 0.239 34.4 132 20 . . .
9041 4 p30 0.264 35.2 160 28 . . .













DOG  TX MAC AUC PAUC 
9048 1 1.15 0 0 
9048 2 1.055 0 0 
9048 3 0.645 279.9 87.5 
9048 4 0.66 150.3 37.7 
9053 1 1.175 0 0 
9053 2 0.975 0 0 
9053 3 0.73 45.86 12.24 
9053 4 1.02 0.9225 0 
9054 1 1.15 0 0 
9054 2 1.03 0 0 
9054 3 0.69 112.1 58.34 
9054 4 0.86 98.75 44.99 
9011 1 0.94 0 0 
9011 2 0.85 0 0 
9011 3 0.86 213.4 57.18 
9011 4 0.56 151.1 45.21 
PACC 1 1.39 0 0 
PACC 2 0.56 0 0 
PACC 3 0.76 237.5 102 
PACC 4 0.94 226.1 103.8 
9041 1 1.375 0 0 
9041 2 0.84 0 0 
9041 3 0.895 118.8 43.02 
9041 4 0.82 58.59 19.58 
 
Abbreviations:  
MAC = Minimum alveolar concentration 
AUC = Area under the curve 
PAUC = Partial area under the curve 
TX = treatment (1= C-NORM, 2= F-NORM, 3= C-HYPO, 4= F-HYPO) 
Fent = fentanyl concentration 
Temp = temperature (°C) 
HR = heart rate 
RR = respiratory rate 
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